Author

Nyingi M. Kemmer

Observed names: Kemmer N, Kemmer, Nyingi, N KEMMER, N Kemmer, N. Kemmer, N.M. Kemmer, Nyingi Kemmer, Nyingi M Kemmer

Observed institutions: University of Miami, University of South Florida, Tampa General Hospital, Kuwait University, Cincinnati VA Medical Center, Conatus Pharmaceuticals (United States), The University of Texas Medical Branch at Galveston, University of Cincinnati, University of Cincinnati Medical Center

ORCID: 0000-0002-4930-0982

Observed ORCID: 0000-0002-4930-0982

OpenAlex ID: A5078622227

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension

2019 · Naga Chalasani, Manal F. Abdelmalek, et al. · Gastroenterology · 358

PDF

Extrahepatic replication of HCV: Insights into clinical manifestations and biological consequences

2006 · Jason T. Blackard, Nyingi Kemmer, et al. · Hepatology · 190

PDF

Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension

2019 · Guadalupe Garcia-Tsao, Jaime Bosch, et al. · Journal of Hepatology · 158

PDF

Alpha-1-Antitrypsin Deficiency: Outcomes After Liver Transplantation

2008 · N. Kemmer, T. Kaiser, et al. · Transplantation Proceedings · 83

Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma

2012 · Abhishek Mathur, Edson S. Franco, et al. · HPB · 76

PDF

Weight Loss and Weight Regain in Usual Clinical Practice: Results From the TARGET-NASH Observational Cohort

2021 · Miguel H. Malespin, Alfred Sidney Barritt, et al. · Clinical Gastroenterology and Hepatology · 75

HEPATITIS A

2000 · Nyingi M. Kemmer, Emil P. Miskovsky · Infectious Disease Clinics of North America · 75

Nonalcoholic Fatty Liver Disease Epidemic and Its Implications for Liver Transplantation

2013 · Nyingi Kemmer, Guy W. Neff, et al. · Transplantation · 67

The Role of Coronary Calcium Score in the Risk Assessment of Liver Transplant Candidates

2014 · N. Kemmer, J. Case, et al. · Transplantation Proceedings · 64

Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis

2020 · Catherine Frenette, Zeid Kayali, et al. · Journal of Hepatology · 62

Analysis of Hospitalizations Comparing Rifaximin Versus Lactulose in the Management of Hepatic Encephalopathy

2006 · G.W. Neff, N. Kemmer, et al. · Transplantation Proceedings · 61

Combination Therapy in Liver Transplant Recipients with Hepatitis B Virus Without Hepatitis B Immune Globulin

2007 · Guy W. Neff, Nyingi Kemmer, et al. · Digestive Diseases and Sciences · 53

Access to Liver Transplantation in the MELD Era: Role of Ethnicity and Insurance

2008 · Nyingi Kemmer, Victoria Zacharias, et al. · Digestive Diseases and Sciences · 50

Outcomes in Adult and Pediatric Liver Transplantation Among Various Ethnic Groups

2007 · G.W. Neff, N. Kemmer, et al. · Transplantation Proceedings · 45

Ethnic disparities in liver transplantation.

2011 · Nyingi Kemmer · PubMed · 39

Review: Predicting the probable outcome of treatment in HCV patients

2009 · Udayakumar Navaneethan, Nyingi Kemmer, et al. · Therapeutic Advances in Gastroenterology · 37

Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series

2010 · Guy Neff, Victoria Zacharias, et al. · Liver Transplantation · 32

Liver Transplantation Trends for Older Recipients: Regional and Ethnic Variations

2008 · Nyingi Kemmer, Kamran Safdar, et al. · Transplantation · 30

Lack of Clostridium difficile Infection in Patients Treated With Rifaximin for Hepatic Encephalopathy

2013 · Guy W. Neff, Michael Jones, et al. · Journal of Clinical Gastroenterology · 29

Impact of Geographic Location on Access to Liver Transplantation Among Ethnic Minorities

2008 · Nyingi Kemmer, Kamran Safdar, et al. · Transplantation · 28

Durability of Rifaximin Response in Hepatic Encephalopathy

2011 · Guy W. Neff, Michael Jones, et al. · Journal of Clinical Gastroenterology · 27

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease

2018 · Eric Lawitz, Edward Gane, et al. · Kidney International Reports · 25

2010 · Nyingi M Kemmer, Kenneth E Sherman · PubMed · 25

Social Determinants of Orthotopic Liver Transplantation Candidacy: Role of Patient-Related Factors

2011 · N. Kemmer, A. Alsina, et al. · Transplantation Proceedings · 24

Managing chronic hepatitis C in the difficult‐to‐treat patient

2007 · Nyingi Kemmer, Guy W. Neff · Liver International · 23

PDF

Works count: 151

Citation count: 2,106

H-index: 24

I10-index: 39